EMA Validates Valneva's Lyme Vaccine MAA; Phase 3 Shows >70% Efficacy

summarizeSummary

Valneva and Pfizer's Lyme disease vaccine candidate has been accepted for review by the European Medicines Agency, based on Phase 3 data showing over 70% efficacy.

check_boxKey Events · Product Development and Regulatory · VALN

• EMA Validates MAA

  The European Medicines Agency has validated the Marketing Authorization Application for PF-07307405, the Lyme disease vaccine candidate developed with Pfizer, and will begin its assessment.

• Phase 3 Efficacy >70%

  The Phase 3 VALOR trial showed efficacy of more than 70% in preventing Lyme disease in individuals aged 5 and older, with no safety concerns identified.

• First-in-Class Opportunity

  There are currently no approved human vaccines for Lyme disease, and over 200 million people live in Lyme disease risk areas in Europe, representing a significant market opportunity.

• Regulatory Review Timeline

  The EMA review process will now proceed, with approval timing dependent on the agency's assessment of the application.

auto_awesomeAnalysis · VALN · Life Sciences

The EMA has accepted the Marketing Authorization Application for PF-07307405, the Lyme disease vaccine candidate from Valneva and Pfizer, triggering the formal review process. This is a major regulatory milestone for a vaccine with no approved competitors and a large addressable market in Europe. The Phase 3 VALOR trial demonstrated over 70% efficacy with no safety concerns, supporting a strong approval case. For Valneva, which reported a tripling of its net loss just yesterday, this progress on its lead pipeline asset is a critical positive development that could transform its commercial outlook if approved.